Online inquiry

IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4261MR)

This product GTTS-WQ4261MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LINGO1 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001301186.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84894
UniProt ID Q96FE5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4261MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6612MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ7640MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ11526MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ9627MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ5077MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ3279MR IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ6732MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ6714MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.